Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EBITDA for 7 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 54.17% to $22.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.0 million through Dec 2025, up 9.21% year-over-year, with the annual reading at $159.0 million for FY2025, 9.21% up from the prior year.
  • EBITDA hit $22.5 million in Q4 2025 for Harmony Biosciences Holdings, down from $51.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $87.8 million in Q3 2022 to a low of -$9.6 million in Q3 2021.
  • Historically, EBITDA has averaged $32.8 million across 5 years, with a median of $31.7 million in 2023.
  • Biggest five-year swings in EBITDA: crashed 192.68% in 2021 and later skyrocketed 1012.62% in 2022.
  • Year by year, EBITDA stood at $22.7 million in 2021, then skyrocketed by 113.68% to $48.5 million in 2022, then plummeted by 44.11% to $27.1 million in 2023, then skyrocketed by 80.8% to $49.0 million in 2024, then crashed by 54.17% to $22.5 million in 2025.
  • Business Quant data shows EBITDA for HRMY at $22.5 million in Q4 2025, $51.0 million in Q3 2025, and $39.8 million in Q2 2025.